Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2016-10-06 Regulatory Filings
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. Form 6-K filings are periodic reports submitted by foreign private issuers to provide information that is material to investors but not required in annual or quarterly reports. The document includes a news release as an exhibit about clinical data but does not contain comprehensive financial statements or detailed financial analysis. The document length is only 2164 characters, which is quite short and does not represent a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2016-10-06 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. Form 6-K filings are periodic reports submitted by foreign private issuers to provide information that is material to investors but not required in annual or quarterly reports. The document includes a news release about clinical trial results but does not contain comprehensive financial statements or detailed financial analysis. The document length is 2170 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, this document fits the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-09-30 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes metadata about the filing, signatures, and an exhibit index referencing a news release about a presentation. The document length is only 2133 characters, indicating it is a short filing. It does not contain detailed financial statements or substantive financial data, nor does it present full annual or quarterly reports. Instead, it serves as a regulatory filing to report current information to the SEC. According to the classification rules, Form 6-K filings are best categorized under Regulatory Filings (RNS) as they are miscellaneous filings that do not fit other specific categories and often provide updates or notices without full report content.
2016-09-26 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. Form 6-K filings are typically used to provide current reports and information that foreign private issuers must disclose to the SEC, but they are not annual reports, earnings releases, or other specific financial reports. The document includes a news release about an upcoming webcast event, which is typical content for a 6-K. The document length is short (2130 characters), and it does not contain detailed financial statements or substantive financial data. Therefore, it does not qualify as an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or other detailed financial filings. It is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-09-26 English
AURINIA PHARMACEUTICALS 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The text includes the SEC header, form type (6-K), filing date, company details, and a signature block. The content is brief (2124 characters) and includes an exhibit index referencing a news release about a presentation at an investment conference. There is no substantive financial data, detailed financial statements, or comprehensive report content. The document serves as a regulatory filing to inform the SEC and investors about a specific event or update, typical of Form 6-K filings. According to the classification rules, such filings fall under Regulatory Filings (RNS) as they do not contain full reports or detailed financial data but are official regulatory announcements.
2016-09-26 English
REPORT OF FOREIGN PRIVATE ISSUER DATED AUGUST 22, 2016
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed pursuant to SEC rules. It is dated August 22, 2016, and includes a Material Change Report as an exhibit. The text does not contain detailed financial statements or comprehensive financial data, but rather serves as a regulatory filing to inform the SEC and investors of material changes. The document length is 2279 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this document fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2016-08-22 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.